Literature DB >> 7041297

A prospective randomized controlled trial of cefoxitin versus clindamycin-aminoglycoside in mixed anaerobic-aerobic infections.

G L Drusano, J W Warren, A J Saah, E S Caplan, J H Tenney, S Hansen, J Granados, H C Standiford, E H Miller.   

Abstract

Ninety patients infected with presumed penicillin resistant anaerobes were randomized to cefoxitin or clindamycin-aminoglycoside. Cefoxitin was comparable to clindamycin-aminoglycoside in cures of intestinal associated, 16 of 26 versus 11 of 21, and pelvic infections, 20 of 20 versus 22 of 23. Cefoxitin-resistant facultative-aerobic gram-negative rods were found in 16 of 45 patients with intestine associated infection. Probable antibiotic associated nephrotoxicity was less frequent in the patients in the cefoxitin group, zero of 46 versus seven of 44, p less than 0.05, although a false creatinine elevation was noted more frequent, seven of 46 versus one of 44, p less than 0.05. Infections causing failure in patients in the cefoxitin group more frequently contained cefoxitin resistant gram-negative rods at the time of failure than did infections causing failure in those in the clindamycin-aminoglycoside group that contained gentamicin-resistant gram-negative rods, eight of eight versus zero of eight, p less than 0.001. Cefoxitin may be adequate therapy for many patients with mixed anaerobic/aerobic infections; however, the addition of an aminoglycoside may be prudent in those with known, or suspected, cefoxitin resistant gram-negative rods.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7041297

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  22 in total

1.  Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins.

Authors:  D Kalman; S L Barriere
Journal:  Tex Heart Inst J       Date:  1990

2.  Anti-anaerobic antimicrobial agents: cefoxitin, cefotetan, clindamycin, and metronidazole.

Authors:  J A Bosso; R A Prince
Journal:  Tex Heart Inst J       Date:  1990

Review 3.  Current antimicrobial therapy of anaerobic infections.

Authors:  C V Sanders; K E Aldridge
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

4.  Efficacy of metronidazole lavage in treatment of intraperitoneal sepsis. A prospective study.

Authors:  S K Saha
Journal:  Dig Dis Sci       Date:  1996-07       Impact factor: 3.199

5.  Cost-effective choice of antimicrobial therapy for serious infections.

Authors:  M C Weinstein; J L Read; D N MacKay; J J Kresel; H Ashley; K T Halvorsen; H C Hutchings
Journal:  J Gen Intern Med       Date:  1986 Nov-Dec       Impact factor: 5.128

6.  Prospective randomized clinical trial assessing the efficacy of a short course of intravenously administered amoxicillin plus clavulanic acid followed by oral antibiotic in patients with uncomplicated acute diverticulitis.

Authors:  Yolanda Ribas; Jordi Bombardó; Francesc Aguilar; Esther Jovell; Manel Alcantara-Moral; Francesc Campillo; Xavier Lleonart; Xavier Serra-Aracil
Journal:  Int J Colorectal Dis       Date:  2010-06-05       Impact factor: 2.571

7.  Randomized prospective study comparing moxalactam and cefoxitin with or without tobramycin for the treatment of serious surgical infections.

Authors:  F P Tally; J M Kellum; J L Ho; T F O'Donnell; M Barza; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

Review 8.  Antibiotic trials in intra-abdominal infections. A critical evaluation of study design and outcome reporting.

Authors:  J S Solomkin; J L Meakins; M D Allo; E P Dellinger; R L Simmons
Journal:  Ann Surg       Date:  1984-07       Impact factor: 12.969

Review 9.  Diverticular disease. Epidemiology and pharmacological treatment.

Authors:  L J Cheskin; R D Lamport
Journal:  Drugs Aging       Date:  1995-01       Impact factor: 3.923

10.  Antibiotic treatment for surgical peritonitis.

Authors:  D M Mosdell; D M Morris; A Voltura; D E Pitcher; M W Twiest; R L Milne; B G Miscall; D E Fry
Journal:  Ann Surg       Date:  1991-11       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.